Loracarbef Brand Name– Lorabid
What is Loracarbef
NOTE: This drug is discontinued in the US.
Loracarbef is an orally administered synthetic beta-lactam antibiotic and is a member of the carbacephem class.
Loracarbef is a synthetic structural analog of the cephalosporin cefaclor. Chemically, the dihydrothiazine ring of the loracarbef structure contains a methylene group where the sulfur atom is present on the cefaclor molecule.
The clinical utility and beta-lactamase stability of loracarbef is similar to that of the second-generation cephalosporins.
Thus loracarbef’s spectrum of activity includes pathogens frequently isolated in respiratory, urinary, skin, and soft-tissue infections.
The side effect profile of loracarbef is similar to that of other cephalosporins. The clinical efficacy of loracarbef is also comparable to that of amoxicillin and amoxicillin/clavulanic acid in patients with upper or lower respiratory tract infections.
Loracarbef was approved by the FDA in December 1991.
The manufacture and distribution of Lorabid® was discontinued in September 2006 for business reasons by King Pharmaceuticals.
There are currently no other suppliers of loracarbef in the U.S.
Indications
- bronchitis
- Citrobacter diversus
- Clostridium perfringens
- cystitis
- Escherichia coli
- Fusobacterium necrophorum
- Haemophilus influenzae (beta-lactamase negative)
- Haemophilus influenzae (beta-lactamase positive)
- Haemophilus parainfluenzae
- impetigo
- Klebsiella pneumoniae
- lower respiratory tract infections
- Moraxella catarrhalis
- Neisseria gonorrhoeae
- otitis media
- Pasteurella multocida
- Peptococcus niger
- Peptostreptococcus intermedius
- pharyngitis
- Propionibacterium acnes
- Proteus mirabilis
- pyelonephritis
- Salmonella sp.
- Shigella sp.
- sinusitis
- skin and skin structure infections
- Staphylococcus aureus (MSSA)
- Staphylococcus epidermidis
- Staphylococcus saprophyticus
- Streptococcus agalactiae (group B streptococci)
- Streptococcus bovis
- Streptococcus dysgalactiae
- Streptococcus pneumoniae
- Streptococcus pyogenes (group A beta-hemolytic streptococci)
- Streptococcus sp.
- tonsillitis
- upper respiratory tract infections
- urinary tract infection (UTI)
- Viridans streptococci
- Yersinia enterocolitica
Side Effects
- abdominal pain
- anaphylactic shock
- anorexia
- candidiasis
- cholestasis
- diarrhea
- dizziness
- elevated hepatic enzymes
- eosinophilia
- erythema multiforme
- headache
- hypoprothrombinemia
- insomnia
- jaundice
- leukopenia
- maculopapular rash
- nausea
- peripheral vasodilation
- pruritus
- pseudomembranous colitis
- seizures
- serum sickness
- Stevens-Johnson syndrome
- superinfection
- thrombocytopenia
- toxic epidermal necrolysis
- urticaria
- vaginitis
- vomiting
Monitoring Parameters
- serum creatinine/BUN
Contraindications
- breast-feeding
- carbapenem hypersensitivity
- cephalosporin hypersensitivity
- colitis
- diarrhea
- geriatric
- GI disease
- infants
- inflammatory bowel disease
- neonates
- penicillin hypersensitivity
- phenylketonuria
- pregnancy
- pseudomembranous colitis
- renal failure
- renal impairment
- ulcerative colitis
Interactions
- Colchicine; Probenecid
- Probenecid
- Sodium picosulfate; Magnesium oxide; Anhydrous citric acid